VenoVision

Jerusalem, Israel

VenoVision is a noninvasive remote monitoring system for cardiorenal and cardiopulmonary patients across the entire hospital stay. Based on patented thermal-imaging technology, the system supports healthcare professionals in reducing fluid imbalance, deterioration, and shock. VenoVision is also designed for use in homes and nursing facilities to monitor for deterioration, thereby reducing preventable ER visits and rehospitalizations. As a noninvasive remote monitoring system, VenoVision is capable of supporting high-risk patients both in the hospital and at home. In hospital settings, the system can be used to detect all stages of deterioration, including fever, respiratory abnormalities, ARDS, SIRS, shock, organ failure, and cardiac arrest. The system can also be used for fluid balance monitoring, as certain trial drugs can lead to dehydration. In the home, the VenoVision system can detect early signs of deterioration in patients with chronic diseases such as heart failure, renal disease, and COPD. It can also be used to collect data for remote assessment by physicians and monitor self-management.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out VenoVision on @MedStartr Today #Cardiopulmonary #CardiovascularRenalMetabolismCVRM #Shock #AcuteCareConditions #RPM #MedMo #MedStartrVentures

https://www.medstartr.ai/s/15WocjHQ-B0

Get Involved in VenoVision

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2022
Website: www.venovision.com/

Disease Areas

Cardiopulmonary Cardiovascular, Renal & Metabolism (CVRM)Shock Acute Care Conditions

Technologies

Remote MonitoringNoninvasiveEarly Warning System

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of VenoVision?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.